GANNET53 a Drug Strategy Targeting Stabilised Mutant P53 to Fight Metastatic Platinum-Resistant Ovarian Cancer EUROPEAN PROJECT

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer

GANNET53 A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer EUROPEAN PROJECT

Sponsor: Medical University of Innsbruck, Austria, Department of Obstetrics and Gynecology Coordinator: Prof. Dr. Nicole Concin

Figure 1: THE GANNET53 PROJECT PARTNERS

ORGANISATION GROUP LEADER Nicole Concin Medical University Innsbruck, AUSTRIA Christian Marth

Ignace Vergote Katholieke Universiteit Leuven, BELGIUM

Jalid Sehouli Charité - Universitätsmedizin Berlin, GERMANY Ioana Braicu

University Medical Centre Hamburg-Eppendorf, Barbara Schmalfeldt GERMANY Sven Mahner

Medical University of Vienna, AUSTRIA Robert Zeillinger

Assistance Publique – Hôpitaux de Paris, FRANCE Eric Pujade-Lauraine Hôpital européen Georges-Pompidou Hôpital Tenon Centre Anticancereux Léon Bérard, FRANCE Isabelle Ray-Coquard

Barbara Schmalfeldt AGO Research GmbH, GERMANY Sven Mahner

PROJECT PARTNERS Medical University Innsbruck • Katholieke Universiteit Leuven • Charité Universitätsmedizin Berlin • Medizinische Universität Wien • Universitätsklinikum Hamburg-Eppendorf • Assistance Publique-Hôpitaux de Paris • Centre Léon Bérard Lyon • AGO Research GmbH • NOGGO eV • ARCAGY GINECO • Universitätsmedizin Göttingen • xailabs GmbH • ONCOLAB Diagnostics GmbH • Kliniken Essen-Mitte • Technische Universität Dresden • Centre François Baclesse Caen • Ernst-Moritz-Arndt-Universität Greifswald • Otto-von-Guericke-Universität Magdeburg

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer

Nord-Ostdeutsche Gesellschaft für Gynaek- Jalid Sehouli ologische Onkologie, GERMAN

ARCAY – GINECO Eric Pujade-Lauraine Association de Recherche dans le Cancers dont

Gynécologique – Groupe des Investigateurs

Nationaux dans l’Etude des Cancers Ovariens,

FRANCE Ute M. Moll University Hospital Goettingen – Matthias Dobbelstein Georg-August University Goettingen, GERMANY

Robert Zeillinger OncoLab Diagnostics GmbH, AUSTRIA

xailabs GmbH, GERMANY Salvatore Vanasco

Kliniken Essen Mitte, Evang. Huyssens- Philipp Harter Stiftung/Knappschaft GmbH, GERMANY

Technical University of Dresden Ulrich Canzler University Hospital Carl Gustav Carus Dresden,

GERMANY

Centre François Baclesse Florence Joly-Lobbedez Centre de Lutte Contre le Cancer (CLCC) de Caen,

FRANCE

University of Greifswald Alexander Mustea

University Clinic Greifswald, GERMANY

University of Magdeburg Atanas Ignatov University Clinic Magdeburg, GERMANY

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer

Figure 2: THE GANNET53 RECRUITMENT STRATEGY

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer

Figure 3: THE GANNET53 PHASE II STUDY DESIGN

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer Figure 4: Proximity Ligation Assay (PLA) detecting Hsp90-mutp53 interaction applied on: FFPE ovarian cancer tissue (left), and ascites of an ovarian cancer patient (right)

Figure 5: Immunofluorecence staining of circulation tumour cells (CTC) from blood samples. A: Positive control of T47D cells spiked in leucocytes of a healthy donor; B: Example of a CTC detected in blood of an ovarian cancer patient.

LEGAL NOTE: All rights to the images displayed in Figures 4 and 5 are reserved by the GANNET53 consortium